{
  "docId": "019dd923-5ca1-7489-b638-42055a53b541",
  "docSlug": "1774c324fda45105",
  "documentTitle": "Pivoting to a High Quality Growth of Clinical Trials in China PharmaDJ x L.E.K. Clinical Development Report",
  "authorId": "LEK",
  "authorName": "L.E.K.",
  "documentKindSlug": "consulting-deck",
  "documentKindLabel": "Consulting deck",
  "sourceTypeSlug": "strategy_consulting",
  "sourceTypeLabel": "Strategy consulting",
  "presentationDate": null,
  "orientation": "landscape",
  "aspectRatio": 1.778,
  "pageNumber": 16,
  "pageCount": 58,
  "prevPage": 15,
  "nextPage": 17,
  "slideType": "market_landscape",
  "function": "analyze_data",
  "density": "dense",
  "nDataPoints": 28,
  "notes": "The chart uses a broken y-axis to accommodate the large number of companies in the 1-5 project range.",
  "elementsJson": [
    "headline_text",
    "bar_chart_stacked",
    "footnote"
  ],
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019dd923-5ca1-7489-b638-42055a53b541/16",
  "deckHref": "/decks/019dd923-5ca1-7489-b638-42055a53b541",
  "deckJsonHref": "/decks/019dd923-5ca1-7489-b638-42055a53b541.json",
  "deckAnchorHref": "/decks/019dd923-5ca1-7489-b638-42055a53b541#slide-16",
  "components": [
    {
      "bbox": {
        "h": 0.675,
        "w": 0.928,
        "x": 0.036,
        "y": 0.215
      },
      "kind": "chart",
      "text": "Distribution of Chinese innovative pharmas by number of class 1 innovative projects* (823 companies in total) (2021)",
      "attrs": null,
      "subkind": "bar-stacked",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "044804ea-9c97-45a6-b6d9-a7718ad6a1d6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.025,
        "w": 0.41,
        "x": 0.036,
        "y": 0.888
      },
      "kind": "disclaimer",
      "text": "Note: * Include domestic and global class-1 new-drug (一类创新药) pipeline or marketed products. Source: DXY, Qichacha, L.E.K. analysis",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "d39e15e9-8960-479a-b8f7-b391ee354c08",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.045,
        "w": 0.156,
        "x": 0.788,
        "y": 0.325
      },
      "kind": "legend",
      "text": "With foreign capital; With Chinese-only capital",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "01429d03-cdbf-4207-811b-56dbb57957fc",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": null,
      "kind": "metric",
      "text": "Number of companies: 823",
      "attrs": null,
      "subkind": "primary",
      "toolName": "Quantification",
      "toolSlug": "quantification",
      "confidence": null,
      "componentId": "019dd951-c7ca-701b-9cbc-543d0c93df6f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.041,
        "w": 0.928,
        "x": 0.036,
        "y": 0.061
      },
      "kind": "title",
      "text": "Chinese pharma companies have surely made some progresses in innovation during the past few years, among which over 800 companies already have Class 1 innovative projects",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6c2f288d-58c0-48b5-a7c2-9ebd1b91e5b6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.016,
        "w": 0.378,
        "x": 0.036,
        "y": 0.033
      },
      "kind": "title",
      "text": "Development of More Innovative and Differentiated Therapies",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b3307573-e4c8-487a-962d-022924ac9ed2",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [
    {
      "metricRaw": "Number of companies",
      "numberRaw": "823",
      "numberKind": "plain",
      "actionTitle": "Chinese pharma companies have surely made some progresses in innovation during the past few years, among which over 800 companies already have Class 1 innovative projects",
      "calloutText": null,
      "numberScale": null,
      "numberValue": 823,
      "metricFamily": "survey_sentiment",
      "numberCurrency": null
    }
  ],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 20,
      "from": 12,
      "beatId": "b805e1f5-4eeb-45d7-a58b-7531d46e8580",
      "arcName": "The Consultant's Gambit",
      "arcSlug": "consultants-gambit",
      "beatName": "Solution & Approach",
      "beatSlug": "consultants-gambit-solution-approach",
      "evidence": "The report proposes a solution, focusing on strategic trends such as development of more innovative and differentiated therapies.",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": "Turn",
      "parentBeatSlug": "turn"
    }
  ],
  "loops": [
    {
      "to": 20,
      "from": 11,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "90bfd894-313f-433e-b1a3-d0f790c2452f",
      "evidence": "The report highlights the challenges facing China's clinical development, including homogeneous competition and a need for more innovative and differentiated therapies.",
      "position": 0,
      "objective": "What are the consequences of not pivoting to high-quality growth in China's clinical trials?",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}